Unicycive Therapeutics, Inc. (NASDAQ: UNCY)

This investigation is for anyone who acquired securities in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) prior to June 30, 2026.

The Law Offices of Howard G. Smith believes that the Company and certain of its executives violated federal law. Specifically, the Law Offices of Howard G. Smith believes that the Company misled investors regarding its financial condition. More specifically, the Law Offices of Howard G. Smith believes that the Company misled investors by telling investors that the Company corrected the manufacturing deficiencies it had producing oxylanthanum when the Company failed to correct the deficiencies.

On June 30, 2026, Unicycive disclosed that the FDA had issued a second Complete Response Letter (“CRL”) regarding the Company’s resubmitted New Drug Application for its kidney disease therapy, oxylanthanum, identifying the “same third-party manufacturing deficiencies that were identified in the previous CRL issued in June 2025.”  On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) prior to June 30, 2026 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.